Anavex Life Sciences has patented a method using ANAVEX2-73 to treat neurodevelopmental disorders like autism, cerebral palsy, and Rett syndrome. The patent also covers conditions related to loss-of-function mutations of the MeCP2 gene. GlobalData’s report on Anavex Life Sciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Anavex Life Sciences Corp - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Anavex Life Sciences, Cancer treatment biomarkers was a key innovation area identified from patents. Anavex Life Sciences's grant share as of January 2024 was 26%. Grant share is based on the ratio of number of grants to total number of patents.

Treatment of neurodevelopmental disorders using anavex2-73

Source: United States Patent and Trademark Office (USPTO). Credit: Anavex Life Sciences Corp

A recently granted patent (Publication Number: US11839600B2) outlines a method for treating conditions associated with loss-of-function mutations of the gene encoding methyl-CpG binding protein 2 (MeCP2) in individuals in need of such treatment. The method involves administering a composition containing a therapeutic agent chosen from Anavex2-73, an analog of Anavex 2-73, or a combination of both. The conditions targeted by this method include a range of symptoms such as abnormal breathing, cardiac function, feeding, choking, weight gain failure, sleep disturbances, seizures, gadolinium-enhancing lesions, among others.

Furthermore, the patent specifies that the conditions linked to MeCP2 mutations may also be associated with neurodevelopmental or neurological diseases like multiple sclerosis, Rett Syndrome, cerebral palsy, Angelman syndrome, Williams syndrome, and autism spectrum disorder. The therapeutic agent, whether Anavex2-73 or its analog, is to be administered in dosages ranging from 0.5 mg/day to 100 mg/day, depending on the age of the subject and the specific disease being treated. The composition can be delivered orally, transdermally, or parenterally, with varying dosages and administration frequencies based on the individual's age and condition, with treatment durations extending from a minimum of 5 days to potentially up to 5 years.

To know more about GlobalData’s detailed insights on Anavex Life Sciences, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies